SHOULD ANTIBODIES TO DOMAIN I B2-GLYCOPROTEIN 1 BE INVESTIGATED IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)?

被引：1
|
作者：
Cheldieva, F. [1 ,2 ]
Reshetnyak, T. [1 ,2 ]
Cherkasova, M. [1 ]
Glukhova, S. [3 ]
Lila, A. [2 ]
Nasonov, E. [3 ]
机构：
[1] VA Nasonova Res Inst Rheumatol, Lab Thromboinflammat, Moscow, Russia
[2] Minist Hlth Russia, Russian Med Acad Continuing Profess Educ, Dept Rheumatol, Moscow, Russia
[3] VA Nasonova Res Inst Rheumatol, Dept Rheumatol, Moscow, Russia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2329
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0496
引用
收藏
页码：1374 / 1375
页数：2
相关论文
共 50 条
  • [1] Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus
    T. M. Reshetnyak
    F. A. Cheldieva
    M. V. Cherkasova
    S. I. Glukhova
    A. M. Lila
    E. L. Nasonov
    Doklady Biochemistry and Biophysics, 2023, 511 : 219 - 226
  • [2] Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus
    Reshetnyak, T. M.
    Cheldieva, F. A.
    Cherkasova, M. V.
    Glukhova, S. I.
    Lila, A. M.
    Nasonov, E. L.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2023, 511 (01) : 219 - 226
  • [3] Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus
    T. M. Reshetnyak
    F. A. Cheldieva
    M. V. Cherkasova
    S. I. Glukhova
    A. M. Lila
    E. L. Nasonov
    Doklady Biochemistry and Biophysics, 2023, 513 (1) : 358 - 358
  • [4] Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL)
    Savelli, Stephanie L.
    Roubey, Robert A. S.
    Kitzmiller, Kathryn J.
    Zhou, Danlei
    Nagaraja, Haikady N.
    Mulvihill, Evan
    Barbar-Smiley, Fatima
    Ardoin, Stacy P.
    Wu, Yee Ling
    Yu, Chack-Yung
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [5] Pregnancy outcome in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).
    Ramos, A
    Veloz, G
    Garcia, J
    Barile, L
    Miranda, JM
    Jara, LJ
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1637 - 1637
  • [6] Secondary antiphospholipid syndrome (APS) in a cohort of greek patients with systemic lupus erythematosus (SLE)
    Papadopoulos, N. G.
    Tsiaousis, G.
    Giannakou, A.
    Pavlitou-Tsiontsi, A.
    Galanopoulou, V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (02) : 139 - 139
  • [7] STRESS FACTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND ANTIPHOSPHOLIPID SYNDROME (APS) PATIENTS COMPARISON
    Borisova, A.
    Lisitsyna, T.
    Veltischev, D.
    Reshetnyak, T.
    Seravina, O.
    Kovalevskaya, O.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S110 - S110
  • [8] B2-glycoprotein I and antiphospholipid syndrome
    Hokkaido Univ Sch of Medicine, Sapporo, Japan
    Isr J Med Sci, 4 (225-238):
  • [9] Ovulation induction therapy in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).
    Du, LTH
    Wechsler, D
    Chalumeau-Costedoat, N
    Vauthier-Brouzes, D
    de Gennes, C
    Lefebvre, G
    Frances, C
    Piette, JC
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S309 - S309
  • [10] The parameters of immune inflammation and haemostasis in patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and without APS
    Arshinov, A., V
    Emanuylov, V., I
    Zubova, N., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 406 - 406
12345